Reimagining a world with predictive health at our fingertips.
HolmesAI is a leader in AIoMT technology for remote patient
monitoring in both hospital and remote patient populations. HolmesAI
leverages extensive expertise in biomedical engineering, data
analytics, chip design, and mobile and cloud software to create
technology that supports decision-making paradigms that achieve
better health and economic outcomes. HolmesAI’s products are
designed for use in a broad range of inpatient and outpatient
settings, such as hospital monitoring, post-discharge care, cardiac
monitoring.
HolmesAI has an experienced commercial and technical leadership team
with a proven track record in the health care market. Additionally,
our large portfolio of intellectual properties, including more-than
20 patents, gives HolmesAI a competitive advantage and scalability.
We believe that the application of AIoMT technology in healthcare is one of the most transformational shifts of our time. Our mission is to make that happen, faster, in the fight against the leading killer globally: cardiac disease.
We started in the Digital Diagnosis R&D Center in SCL, a machine learning scientist conducting basic and translational research in the application of machine learning in cardiology. We worked together, night and day, to try to answer the question: can we prevent heart disease? We saw a need for a different kind of technology, a platform that brings together clinical, engineering and data expertise to power new waves of innovation. That’s why we founded HolmesAI.
‘SCL Group’
The SCL Group(Best Healthcare Group in Korea) was launched in 1983 as a medical institution specializing in clinical trials. Since the foundation, SCL Group has consistently pursued the three core values of quality, service and R&D. As the most professional committed research institution in Korea, SCL Group will continuously do our best by putting our customers first and become a patient-oriented international clinical research institution by studying state-of-the-art medicine based on evidence.
